Semax Information & Coordination for Licensed U.S. Clinics
Semax is the common name used for a seven-amino-acid peptide that has been discussed in research and pharmacy-compounding contexts.
FDA evaluated Semax free base and Semax acetate in 2026 as part of its review of bulk drug substances considered for use under section 503A of the Federal Food, Drug, and Cosmetic Act. Neither substance is a component of an FDA-approved drug.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, publicly available regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About Semax
“Semax” should not be treated as the name of a standardized FDA-approved medication.
FDA evaluated Semax free base and Semax acetate as separate bulk drug substances. The agency also noted inconsistencies in how Semax-related substances have been identified and characterized and states that Semax is a common name rather than a United States Adopted Name.
FDA reviewed the available evidence in connection with proposed uses involving cerebral ischemia, migraine, and trigeminal neuralgia. The agency found insufficient evidence of effectiveness for the Semax-related substances it evaluated.
Phoenix therefore does not promote Semax for cognitive enhancement, neuroprotection, memory, focus, neurological recovery, migraine, pain, or other treatment outcomes.
Current FDA and Compounding Status
Nominations involving Semax-related bulk drug substances were withdrawn. FDA nevertheless chose to continue evaluating Semax free base and Semax acetate on its own initiative.
FDA states that neither substance has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug.
After reviewing physicochemical characterization, historical compounding information, effectiveness, and safety, FDA concluded that the available criteria weigh against adding Semax free base or Semax acetate to the 503A Bulks List.
In July 2026, FDA proposed that Semax free base and Semax acetate not be included on the 503A Bulks List.
That proposal should not be described as a final FDA rule by itself. FDA’s briefing materials explain that the agency does not make its final determination until advisory-committee input has been considered and its reviews are complete.
A pharmacy’s 503A status or an outsourcing facility’s 503B registration also does not automatically establish that a particular bulk substance may be used in compounding. Federal law places separate conditions on bulk drug substances under those frameworks.
Why Product Identity Matters
FDA found inconsistencies in the information submitted for Semax-related substances.
The agency separately evaluated Semax free base and Semax acetate because they are different bulk drug substances. FDA also noted that salts, derivatives, and different active moieties have appeared commercially under similar Semax terminology.
For a clinic, that makes the underlying documentation important. A product name alone does not establish identity, FDA approval, compounding eligibility, quality, or clinical suitability.
Phoenix can help organize available documentation and regulatory information so the clinic can identify questions that require further professional review.
How Phoenix Meds Supports Licensed Clinics
Our work is administrative.
Licensed healthcare organizations may use Phoenix for help reviewing professional credentials, organizing supporting records, checking publicly available licensing and regulatory information, and identifying gaps or inconsistencies in documentation.
When questions remain, we help organize them so they can be reviewed by the appropriate licensed, regulatory, or legal professional.
The purpose is to reduce administrative back-and-forth while keeping clinical, pharmaceutical, and legal responsibilities with the parties responsible for them.
Our review is not FDA approval, pharmacy accreditation, a treatment recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA identified several unresolved issues in its 2026 Semax review.
For the proposed injectable and intranasal dosage forms, FDA cited potential immunogenicity associated with peptide aggregation and peptide-related impurities.
The agency states that available information is insufficient to conclude that Semax free base or Semax acetate does not present those risks.
FDA also found shortcomings in the available characterization and quality information and insufficient evidence supporting effectiveness for the uses it evaluated.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of Semax. We also do not certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Semax Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding credential review, documentation, and publicly available regulatory information relevant to a Semax-related professional inquiry. An administrative inquiry is not a medication order and does not establish product availability, compounding eligibility, FDA approval, or clinical appropriateness.
Clinic Verification
Licensed healthcare organizations may submit relevant professional and facility credentials for administrative verification.
Documentation Review
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Is Semax FDA approved?
FDA evaluated Semax free base and Semax acetate in 2026 and proposed that neither be included on the 503A Bulks List. The advisory process is not itself a final agency determination, so clinics should check current FDA information before relying on a particular status
Are Semax free base and Semax acetate the same substance?
No. FDA treats them as separate bulk drug substances and active pharmaceutical ingredients.
Does FDA consider the evidence for Semax established?
FDA concluded that there was insufficient evidence of effectiveness for the uses it evaluated, including cerebral ischemia, migraine, and trigeminal neuralgia.
Does Phoenix Meds compound or dispense Semax?
No. Phoenix does not compound, manufacture, dispense, test, ship, or take custody of Semax.
What can Phoenix Meds help a clinic with?
Our work is administrative and may include credential review, document organization, review of publicly available regulatory information, and professional communication.
Does Phoenix Meds provide Semax dosing or treatment protocols?Does Phoenix provide Semax dosing or treatment protocols?
No. We do not provide patient-specific dosing, treatment protocols, or clinical recommendations.
Does Phoenix Meds guarantee Semax quality or safety?
No. Phoenix does not test Semax or certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, drug manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present Semax as an FDA-approved treatment and does not establish that a particular compounding or distribution pathway is available or permitted.